Tryton Announces Events at EuroPCR
Two-Hour Session Will Feature Two Live Cases; Pooled Analysis of Bifurcation Stent System Will Examine Evidence from Eight Clinical Studies

Durham, N.C. – May 9, 2012 – Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced activities highlighting the latest experience with the TRYTON Side Branch Stent at EuroPCR, the official congress of the European Association of Percutaneous Cardiovascular Interventions, taking place at the Palais des Congrès May 15-18, 2012 in Paris.

• On Wednesday, May 16 from 2:00 p.m. to 4:00 p.m. in the Theatre Bordeaux, William Wijns, M.D., and Martin B. Leon, M.D., will chair a “Tools and Techniques” session featuring two live transmissions of patients treated using the Tryton stent by Eulogio Garcia, M.D., at the Hospital Clinico San Carlos in Madrid, Spain.

• On Thursday, May 17, at 11:22 a.m. in Room 341, Maik Grundeken, M.D., of the Department of Cardiology at the University of Amsterdam in the Netherlands, will present a patient-level pooled analysis of six-month clinical outcomes from more than 900 patients treated with the Tryton stent in eight post-marketing registries.

• In addition, the conference will feature more than 10 Tryton case reports and three abstracts presenting data related to the Tryton stent system.

The Tryton stent has now been used to treat approximately 5,000 patients and is commercially available throughout Europe, Russia and the Middle East. The company recently began enrollment in the first and only randomized controlled U.S. IDE pivotal clinical trial evaluating a dedicated bifurcation stent. The 704-patient study compares a Tryton stent in the side branch vs. the use of balloon angioplasty in the side branch, with both arms of the trial utilizing a standard drug eluting stent in the main vessel. The trial has completed its IVUS angiographic sub study cohorts and enrollment remains on schedule to complete enrollment later this year. The results of the trial will be submitted to the U.S. Food and Drug Administration (FDA) for approval to market the device in the United States.

Clinical data presented on more than 1,000 patients treated with the Tryton stent has demonstrated consistent target lesion revascularization rates of less than four percent and low thrombosis rates at six-month follow up and beyond.
About Coronary Bifurcation Disease
Coronary artery disease often results in the buildup of plaque at the site of a bifurcation, where one artery branches from another. Current approaches to treating these lesions are time consuming and technically difficult. As a result, the side branch is often left unstented, leaving it vulnerable to higher rates of restenosis, the re-narrowing of the stented vessel following implantation. In patients undergoing PCI-stenting, approximately one-third have a bifurcation lesion. Left main disease, an accumulation of plaque that narrows the base of the coronary tree, is a persistent challenge in interventional cardiology, as more than 75 percent of left main lesions are bifurcation lesions.

About the Tryton Side Branch Stent
The Tryton Side Branch Stent System is built for bifurcation using proprietary Tri-zone™ technology to offer a dedicated strategy for treating bifurcation lesions. Tryton’s cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel. The stent system has received CE Mark and is commercially available throughout Europe, Russia and the Middle East. It is approved in the United States for investigational use only.

About the Randomized Tryton IDE Pivotal Study
The landmark Tryton pivotal study is a multi-national randomized trial that compares a Tryton stent in the side branch vs. the use of balloon angioplasty in the side branch, with both arms of the trial utilizing a standard drug eluting stent in the main vessel. The study, which is the first and only randomized IDE pivotal clinical trial evaluating a dedicated bifurcation stent, will enroll 704 patients at up to 75 centers in North America, Europe and Israel. Martin Leon, M.D. (Columbia University, New York) serves as principal investigator for the study and Patrick Serruys (Thoraxcenter, Rotterdam) is leading IVUS and three-dimensional angiographic analysis.

About Tryton Medical, Inc.
Tryton Medical, Inc., located in Durham, N.C., is a leading developer of novel stent systems for the treatment of bifurcation lesions. The company was founded in 2003 by Aaron V. Kaplan, M.D. (professor of medicine at Dartmouth Medical School/Dartmouth-Hitchcock Medical Center) and Dan Cole to develop stents for the definitive treatment of bifurcation lesions. Privately held, Tryton is backed by Arnerich Massena & Associates, Spray Ventures, PTV Sciences, and RiverVest Ventures. For more information please visit www.trytonmedical.com.

# # #

Media Contact:
Nicole Osmer
nicole@nicoleosmer.com
(650) 454-0504